We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market
News

Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market

Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market
News

Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics has announced that the NASDAQ Listing Qualifications Staff has determined that the Company is in compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market® as set forth in NASDAQ Listing Rule 5550(b)(1).

NASDAQ will continue to monitor the Company's periodic reports to confirm the Company's ongoing compliance with the stockholders' equity requirement.

"As a result of our recently announced registered direct offerings, we were successful in increasing stockholders' equity beyond NASDAQ's listing requirement. We are very pleased to have regained compliance with the rule," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

Berlin continued, "With this determination by NASDAQ, we are now in compliance with the continued listing requirements of The NASDAQ Capital Market."

Advertisement